Sertraline versus other antidepressive agents for depression

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2009, Pages

  Cipriani, Andrea ^a   La Ferla, Teresa ^b   Furukawa, Toshi A ^c   Signoretti, Alessandra ^a   Nakagawa, Atsuo ^d   Churchill, Rachel ^e   McGuire, Hugh ^f   Barbui, Corrado ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^d KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e UNIVERSITY OF BRISTOL   (United Kingdom)

^f National Collaborating Centre for Women's and Children's Health   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CHLORAL HYDRATE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOSULEPIN; DULOXETINE; ESCITALOPRAM; FLUNITRAZEPAM; FLUOXETINE; FLUVOXAMINE; HYPERICUM EXTRACT; IMIPRAMINE; MAPROTILINE; MILNACIPRAN; MIRTAZAPINE; MOCLOBEMIDE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; REBOXETINE; SERTRALINE; TEMAZEPAM; TIANEPTINE; TRAZODONE; UNINDEXED DRUG; VENLAFAXINE; ZOLPIDEM; SEROTONIN UPTAKE INHIBITOR;

ABDOMINAL PAIN; AGITATION; ANOREXIA; ANORGASMIA; ANXIETY; APPETITE; CLINICAL TRIAL; COCHRANE LIBRARY; CONSTIPATION; DIARRHEA; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG TOLERABILITY; DYSPEPSIA; EJACULATION DISORDER; EYE DISEASE; FATIGUE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HEALTH SERVICE; HUMAN; HYPOTENSION; INSOMNIA; LIBIDO; MAJOR DEPRESSION; MEDLINE; META ANALYSIS; MONOTHERAPY; NAUSEA; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PATIENT ATTITUDE; QUALITY OF LIFE; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIAL STATUS; SOMNOLENCE; SUICIDE; SWEATING; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; URINARY DYSFUNCTION; VOMITING; WEIGHT GAIN; XEROSTOMIA; DEPRESSION; RANDOMIZED CONTROLLED TRIAL; CHEMICALLY INDUCED DISORDER; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; DEPRESSION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; DIARRHEA; TREATMENT OUTCOME;

EID: 67549083594     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006117.pub2     Document Type: Review

References (140)

1. * Aberg-Wistedt A, Agren H, Ekselius L, Bengtson F, Akerblad A.C. Sertraline versus paroxetine inmajor depression: clinical outcome after six months of continuous therapy. Journal of Clinical Psychopharmacology 2000;20:645-652
2. Khoury A, Aberg Wistedt A, Stain Malmgren R. Effect of sertraline and paroxetine treatment on depression scores and peripheral indices of serotonergic function in major depression. 11th European College of Neuropsychopharmacology Congress. Paris, France. 31st October 4th November 1998 1998.
3. Aguglia E, Casacchia M, Cassano G.B, Faravelli C, Ferrari G, Giordano P, Pancheri P, Ravizza L, Trabucchi M, Bolino F, Scarpato A, Berardi D, Provenzano G, Brugnoli R, Rozzini R. Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression. International Clinical Psychopharmacology 1993;8:197-202. (Pubitemid 23294927)
4. Alexopoulos G, Gordon J, Zhang D. A placebo-controlled trial of escitalopram and sertraline in the treatment of major depressive disorder. Poster presented at the Annual Meeting of the American College of Neuropsychopharmacology, December, 2004.
5. Baca E, Gonzalez de Chavez M, Garcia-Toro M, Perez-Arnau F, Porras-Chavarino A. Sertraline is more effective than imipramine in the treatment of non-melancholic depression: results from a multicentre, randomized study. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2003;27:493-500. (Pubitemid 36403742)
6. Behan P.O, Hannifah H. 5-HT reuptake inhibitors in CFS. EOS Rivista di Immunologia ed Immunofarmacologia 1995;15:66-69
7. Behnke K, Sogaard J, Martin S, Bauml J, Ravindran A.V, Agren H, Vester-Blokland E.D. Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study. Journal of Clinical Psychopharmacology 2003;23:358-364 (Pubitemid 36951177)
8. Bennie E.H, Mullin J.M, Martindale J.J. A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression. Journal of Clinical Psychiatry 1995;56:229-237
9. Bersani G, Rapisarda V, Ciani N, Bertolino A, Sorge G. A double-blind comparative study of sertraline and amitriptyline in outpatients with major depressive episodes. Human Psychopharmacology 1994;9:63-68 (Pubitemid 24110299)
10. Bondareff W, Alpert M, Friedhoff A.J, Richter E.M, Clary C.M, & Batzar E. Comparison of sertraline and nortriptyline in the treatment ofmajor depressive disorder in late life. American Journal of Psychiatry 2000;157(5):729-736 (Pubitemid 30249651)
11. Boyer P, Danion J.M, Bisserbe J.C, Hotton J.M, Troy S. Clinical and economic comparison of sertraline and fluoxetine in the treatment of depression A 6-month double-blind study in a primary-care setting in France. Pharmacoeconomics 1998;13:157-169 (Pubitemid 128708620)
12. Brenner R, Azbel V, Madhusoodanan S, Pawlowska M. Comparison of an extract of hypericum (LI 160) and sertraline in the treatment of depression: a double-blind, randomized pilot study. Clinical Therapeutics 2000;22:411-419 (Pubitemid 30304793)
13. Chen Z.M, Zhang J.H, Li Z.W, Zhang H.M. Venlafaxine vs imipramine, sertraline in treating depression. Chinese Journal of New Drugs and Clinical Remedies 2001;20:109-111
14. Cohn C.K, Shrivastava R, Mendels J, Cohn J.B, Fabre L.F, Claghorn J.L, Dessain E.C, Itil T.M, Lautin A. Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients. Journal of Clinical Psychiatry 1990;51:28-33.
15. Coleman C.C, Cunningham L.A, Foster V.J, Batey S.R, Donahue R.M.J, Houser T.L, Ascher J.A. Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment. Annals of Clinical Psychiatry 1999;11:205-215
16. Croft H, Settle E.Jr, Houser T, Batey S.R, Donahue R.M.J, Ascher J.A. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clinical Therapeutics 1999;21:643-658 (Pubitemid 29252088)
17. Davidson J.R, Gadde K.M, Fairbank J.A, Rama Krishnan K.R, Califf R.M, Binanay C, Parker C.B, Pugh N, Hartwell T.D, Vitiello B, Ritz L, Severe J, Cole J.O, De Battista C, Doraiswamy P.M, Feighner J.P, Keck P, Kelsey J, Lin K.M, Londborg P.D, Nemeroff C.B, Schatzberg A.F, Sheehan D.V, Srivastava R.K, Taylor L, Trivedi M.H, Weisler R.H. Effect of Hypericum perforatum (St John's Wort) in major depressive disorder: A randomized controlled trial. JAMA 2002;287:1807-1814 (Pubitemid 34303625)
18. Doogan DP, Langdon CJ. A double-blind, placebo-controlled comparison of sertraline and dothiepin in the treatment of major depression in general practice. International Clinical Psychopharmacology 1994;9(2):95-100. (Pubitemid 24160564)
19. Edwards R.A, Newburn G.L. A double blind trial comparing clomipramine and sertraline in the treatment of major depression. Priory Lodge Education Limited www.cityscape.co.uk/users/ad88/sertrl.html 1996.
20. Eker S.S, Akkaya C, Akgoz S, Sarandol A, Kirli S. Comparison of reboxetine and sertraline in terms of efficacy and safety in major depressive disorder. Turk Psikiyatri Dergisi 2005;16(3):153-163
21. Ekselius L, von Knorring L, Eberhard G. A double-blind multicenter trial comparing sertraline and citalopram in patients with major depression treated in general-practice. International Clinical Psychopharmacology 1997;12:323-331 (Pubitemid 28133230)
22. Fava M, Rosenbaum J.F, Hoog S.L, Tepner R.G, Kopp J.B, Nilsson M.E. Fluoxetine versus sertraline and paroxetine inmajor depression: tolerability and efficacy in anxious depression. Journal of Affective Disorders 2000;59:119-126 (Pubitemid 30317428)
23. Fava M, Hoog S.L, Judge R.A, Kopp J.B, Nilsson M.E, Gonzales J.S. Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia. Journal of Clinical Psychopharmacolog 2002;22:137-147 (Pubitemid 34289388)
24. Feiger A, Kiev A, Shrivastava R.K, Wisselink P.G, Wilcox C.S. Nefazodone versus sertraline in outpatients with major depression: Focus on efficacy, tolerability, and effects on sexual function and satisfaction. Journal of Clinical Psychiatry 1996;57:53-62. (Pubitemid 26146710)
25. Forlenza O.V, Almeida O.P, Stoppe A.Jr, Hirata E.S, Ferreira R.C.R. Antidepressant efficacy and safety of low-dose sertraline and standard-dose imipramine for the treatment of depression in older adults: Results from a double-blind, randomized, controlled clinical trial. International Psychogeriatrics 2001;13:75-84.
26. Fournier J.P, Lane R.M, Chouinard G, Watson D.B, Amin M, Remick R.A, Thorpe L.U. A double-blind comparison of sertraline and imipramine in outpatients with major depression: Acute (8 weeks) and continuation (16 weeks) treatment. Human Psychopharmacology 1997;12:203-215 (Pubitemid 27276209)
27. Gastpar M, Singer A, Zeller K. Efficacy and tolerability of hypericum extract STW3 in long-term treatment with a once-daily dosage in comparison with sertraline. Pharmacopsychiatry 2005;38:78-86. (Pubitemid 40388787)
28. Hegerl U, Gallinat J, Moeller H.J, Arato M, Janka Z. Sertraline versus amitriptyline in hospitalized patients with major depression. Pharmacopsychiatry 1997;30:175.
29. Kamijima K, Koyama T, Mita T, Yamauchi T, Asai M, Toru M, Tamura A, Ushijima S, Hasegawa K, Murasaki M, Kosaka K, Yamaguchi N, Nakajima T, Saito M, Kudo Y, Watanabe S, Tashiro N, Kurihara M, Miura S. A double-blind, group comparison study of sertraline by hydrochloride vs amitriptyline hydrochloride. Japanese Journal of Neuropsychopharmacology 1997;19:529-548
30. Kavoussi R.J, Segraves R.T, Hughes A.R, Ascher J.A, Johnston J.A. Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. Journal of Clinical Psychiatry 1997;58:532-537 (Pubitemid 28100273)
31. Lee M.S, Kim S.H, Suh K.Y, Kwak D.I. Efficacy of sertraline in dysthymia. Neuropsychopharmacology 1994;10:222S.
32. Lepine J.P, Goger J, Blashko C, Probst C, Moles M.F, Kosolowski J, Scharfetter B, Lane Roger M. A double-blind study of the efficacy and safety of sertraline and clomipramine in outpatients with severe major depression. International Clinical Psychopharmacology 2000;15:263-271 (Pubitemid 30660961)
33. Li J.H, Kong Q.R, Li S.M. A comparative study of sertraline and maprotiline in the treatment of depression. Shandong Journal of Psychological Medicine 2001;14:173-175
34. Lydiard R.B, Stahl S.M, Hertzman M, Harrison W.M. A double-blind, placebo-controlled study comparing the effects of sertraline versus amitriptyline in the treatment of major depression. Journal of Clinical Psychiatry 1997;58:484-491 (Pubitemid 27527444)
35. Mehtonen O.P, Sogaard J, Roponen P, Behnke K. Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Journal of Clinical Psychiatry 2000;61:95-100. (Pubitemid 30141641)
36. Moller H.J, Glaser K, Leverkus F, Gobel C. Double-blind, multicenter comparative study of sertraline versus amitriptyline in outpatients with major depression. Pharmacopsychiatry 2000;33:206-212
37. Moon C.A, Jago W, Wood K, Doogan D.P. A double-blind comparison of sertraline and clomipramine in the treatment of major depressive disorder and associated anxiety in general-practice. Journal of Psychopharmacology 1994;8:171-176 (Pubitemid 24296901)
38. Munizza C. A Comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder.. Current medical research and opinion 2006;22:1703-1713. (Pubitemid 44449227)
39. Murasaki M, Kamijima K, Yamashita I, Mita T, Yamauchi T, Asai M, Toru M, Tamura A, Ushijima S, Nakajima T, Saito M, Kudo Y, Watanabe S, Tashiro N, Kurihara M, Miura S. Clinical evaluation of sertraline hydrochloride, a selective serotonin reuptake inhibitor for depression and depressive state-A double-blind study compared with imipramine hydrochloride. Japanese Journal of Meuropsychopharmacology 1997;19:505-527 (Pubitemid 27297316)
40. Nemeroff C.B, Ninan P.T, Ballenger J, Lydiard R.B, Feighner J, Patterson W.M, Greist J.H. Double-blind multicenter comparison of fluvoxamine versus sertraline in the treatment of depressed outpatients. Depression 1995;3:163-169 (Pubitemid 26151502)
41. Newhouse PA, Krishnan KR, Doraiswamy PM. A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients. J Clin Psychiatry 2000;61:559-568.
42. Orsel Donbak S, Turkcapar M.H, Ozturk Kilic E.Z, Demirergi N, Akdemir A, Sirin A, Ozbay M.H. Moclobemide and sertraline in the treatment of depressive disorders: a comparative study. Acta Psychiatrica Belgica 1995;95:139-151
43. Oslin D.W, Ten Have T.R, Streim J.E, Datto C.J, Weintraub D, DiFilippo S, Katz I.R. Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents. Journal of Clinical Psychiatry 2003;64:875-882 (Pubitemid 37022752)
44. Quednow B.B, Kuhn K.U, Stelzenmuelle R, Hoenig K, Maier W, Wagner M. Effects of serotonergic and noradrenergic antidepressants on auditory startle response in patients with major depression. Psychopharmacology 2004;175:399-406. (Pubitemid 39362037)
45. Ravindran A.V, Teehan M.D, Bakish D, Yatham L, O'Reilly R, Fernando N.L, Manchanda R, Charbonneau Y, Buttars J. The impact of sertraline, desipramine, and placebo on psychomotor functioning in depression.. Human Psychopharmacology 1995;10:273-281
46. Reimherr F.W, Chouinard G, Cohn C.K, Cole J.O, Itil T.M, LaPierre Y.D, Masco H.L, Mendels J. Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. Journal of Clinical Psychiatry 1990;51:18-27.
47. * Rossini D. Sertraline versus Fluvoxamine in the treatment of elderly Patients with major Depression a double-blind, randomized trial.. Journal of Clinical Psychopharmacology 2005;25:471-475.
48. Sechter D, Troy S, Paternetti S, Boyer P. A double-blind comparison of sertraline and fluoxetine in the treatment of major depressive episode in outpatients. European Psychiatry: the Journal of the Association of European Psychiatrists 1999;14:41-48 (Pubitemid 30700516)
49. Shelton R.C. A randomized, double-blind, active-control study of Sertraline versus Venlafaxine XR in Major Depressive Disorder. Journal of Clinical Psychiatry 2006;67:1674-1681. (Pubitemid 44955146)
50. Sir A. Randomized Trial of Sertraline Versus Venlafaxine XR in Major Depression: Efficacy and Discontinuation Symptoms. Journal of Clinical Psychiatry 2005;66:1312-1320. (Pubitemid 41546512)
51. Sogaard J, Lane R, Latimer P, Behnke K, Christiansens P.E, Nielsen B, Ravindran A.V, Reesal R.T, Goodwin D.P. A 12-week study comparing moclobemide and sertraline in the treatment of outpatients with atypical depression. Journal of Psychopharmacology 1999;13:406-414 (Pubitemid 30055186)
52. Stahl S.M. Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline. Biological Psychiatry 2000;48:894-901. (Pubitemid 30802238)
53. Suri R.A, Altshuler L.L, Rasgon N.L, Calcagno J.L, Frye M.A, Gitlin M.J, Hwang S, Zuckerbrow-Miller J. Efficacy and response time to sertraline versus fluoxetine in the treatment of unipolar major depressive disorder. Journal of Clinical Psychiatry 2000;61:942-946 (Pubitemid 32058010)
54. Szadoczky E, Furedi J. Efficacy and acceptability of tianeptine and sertraline in the acute treatment phase of depression. Encephale 2002;28:343-349
55. Thase M, Simmons J, Howland R, Fava M. Double-blind, Randomized Comparision of Mirtazapine and Sertraline in Depressed Patients who had not responded to SSRI treatment. 52nd Institute on Psychiatric Services - American Psychiatric Association Meeting. Philadelphia, Pa, Usa, 2000.
56. Tsutsui S, Okuse S, Sasaki D. Clinical evaluation of sertraline hydrochloride, a selective serotonin reuptake inhibitor in the treatment of depression and depressive state: a double-blind, group comparison study of sertraline hydrochloride vs trazodone hydrochloride. Shinkeiseishinyakuri 1997;19:549-568 (Pubitemid 27297318)
57. Van Gurp G, Meterissian G.B, Haiek L.N, McCusker J, Bellavance F. St John's wort or sertraline? Randomized controlled trial in primary care. Canadian Family Physician 2002;48:905-912 (Pubitemid 34678961)
58. Van Moffaert M, Bartholome F, Cosyns P, De Nayer A.R, Mertens C. A controlled comparison of sertraline and fluoxetine in acute and continuation treatment of major depression. Human Psychopharmacology 1995;10:393-405.
59. Ventura D, Armstrong E P, Skrepnek GH, Erder M H. Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial. Current Medical Research and Opinion 2007;23(2):245-250. (Pubitemid 46333371)
60. Zanardi R, Franchini L, Gasperini M, Perez J, Smeraldi E. Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. American Journal of Psychiatry 1996;153:1631-1633 (Pubitemid 26406178)
61. Davidson J. A placebo controlled clinical trial of a standardized extract of hypericum perforatum in major depressive disorder. ClinicalTrials. gov 2004.
62. Fava M, Nierenberg AA, Quitkin FM, Zisook S, Pearlstein T, Stone A, & Rosenbaum JF. A preliminary study on the efficacy of sertraline and imipramine on anger attacks in atypical depression and dysthymia. Psychopharmacology Bulletin 1997;33(1):101-103. (Pubitemid 27184201)
63. Finkel S, Richter E. Double-blind comparison of sertraline and nortriptyline in late-life depression. 8th ECNP (European College of Neuropsychopharmacology) Congress. Venice, Italy, 1995.
64. Gonul AS, Yabanoglu I, Reyhancan M, & Oguz A. Selective serotonin reuptake inhibitors: discontinuation rates due to side effects. European Neuropsychopharmacology 1999;9(Suppl 5):215.
65. Latimer PR, Ravindran AV, Bernatchez JP, Fournier JP, Gojer JA, Barratt K, & Buttars J. A sixmonth comparison of toleration and efficacy of sertraline and fluoxetine treatment ofmajor depression. XXth Collegium Internationale Neuro psychopharmacologicum. Melbourne, Australia, 1996.
66. Vovin R, Mazo G, & Ivanov M. Treatment of major depression: Sertraline or amitriptyline. XXIst Collegium Internationale Neuro psychopharmacologicum. Glasgow, Scotland, 1998.
67. Malt UF, Robak OH, Madsbu HP, Bakke O, Loeb M. The Norwegian naturalistic treatment study of depression in general practice (NORDEP)-I: randomised double blind study. British Medical Journal 1999;318:1180-1184 (Pubitemid 29201575)
68. Als-Nielsen B, Chen W, Gluud C, Kjaergard LL.Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?. JAMA 2003;290(7):921-928. (Pubitemid 37430464)
69. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200.
70. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. Journal of Affective Disorders 2000;58:19-36. (Pubitemid 30173208)
71. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-III). 3rd Edition. Washington, DC: American Psychiatric Association, 1980..
72. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R). 3rd Edition. Washington, DC: American Psychiatric Association, 1987.
73. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association, 1994.
74. Barbui C, Hotopf M, Freemantle N, Boynton J, Churchill R, Eccles MP, et al.Treatment discontinuation with selective serotonin reuptake inhibitors (SSRIs) versus tricyclic antidepressants (TCAs). Cochrane Database of Systematic Reviews 2000, Issue 4. [DOI: 10.1002/14651858.CD002791.pub2]
75. Barbui C, Guaiana G, Hotopf M. Amitriptyline for inpatients and SSRIs for outpatients with depression? Systematic review and meta-regression analysis. Pharmacopsychiatry 2004;37(3):93-97 (Pubitemid 38680328)
76. Bauer M, Whybrow PC, Angst J, Versiani M, Möller HJ, World Federation of Societies Biological Psychiatry Task Force on Treatment Guidelines for Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 2002;3(1):5-43.
77. Bhandari M, Busse JW, Jackowski D, Montori VM, Schunemann H, Sprague S, et al.Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. CMAJ 2004;170(4):477-480 (Pubitemid 38293642)
78. Bollini P, Pampallona S, Tibaldi G, Kupelnick B, Munizza C. Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials. British Journal of Psychiatry 1999;174:297-303. (Pubitemid 29179711)
79. Buchkowsky SS, Jewesson PJ. Industry sponsorship and authorship of clinical trials over 20 years. Annals of Pharmacotherapy 2004;38:579-585 (Pubitemid 38352217)
80. Cipriani A, Brambilla P, Furukawa TA, Geddes J, Gregis M, Hotopf M, Malvini L, Barbui C. Fluoxetine versus other types of pharmacotherapy for depression. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD004185.pub2]
81. Cipriani A, Pontarollo F, Signoretti A, Furukawa TA, Nakagawa A, Churchill R, McGuire HF and Barbui C for the Meta-Analysis of New Generation Antidepressants (MANGA) Study Group. Escitalopram versus other antidepressive agents for depression. (Protocol). Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD006532]
82. Cipriani A, Signoretti A, Furukawa TA, Churchill R, Tomelleri S, Omori IM, McGuire HF and Barbui C for the Meta-Analysis of New Generation Antidepressants (MANGA) Study Group. Venlafaxine versus other anti-depressive agents for depression. Cochrane Database of Systematic Reviews 2007, Issue 2.
83. Cipriani A, Furukawa TA, Veronese A, Watanabe N, Churchill R, McGuire HF and Barbui C for the Meta-Analysis of New Generation Antidepressants (MANGA) Study Group. Paroxetine versus other anti-depressive agents for depression. Cochrane Database of Systematic Reviews 2007, Issue 2.
84. Cipriani A, Geddes JR, Barbui C. Venlafaxine for major depression. BMJ 2007;334(7587):215-216
85. Ciuna A, Andretta M, Corbari L, Levi D, Mirandola M, Sorio A, et al.Are we going to increase the use of antidepressants up to that of benzodiazepines?. European Journal of Clinical Pharmacology 2004;60(9):629-634 (Pubitemid 40064595)
86. Davies SJ, Jackson PR, Potokar J, Nutt DJ. Treatment of anxiety and depressive disorders in patients with cardiovascular disease. BMJ 2004;328(7445):939-943 (Pubitemid 38496991)
87. Ellis P. Australian and New Zealand clinical practice guidelines for the treatment of depression. Australian and New Zealand Journal of Psychiatry 2004;38(6):389-407. (Pubitemid 39029045)
88. Feiger AD, Flament MF, Boyer P, Gillespie JA. Sertraline versus fluoxetine in the treatment of major depression: a combined analysis of five double-blind comparator studies. International Clinical Psychopharmacology 2003;18(4):203-210 (Pubitemid 36871871)
89. Feinstein RE, Blumenfield M, Orlowski B, Frishman WH, Ovanessian S. In a national survey of cardiovascular physicians' beliefs and clinical care practices when diagnosing and treating depression in patients with cardiovascular disease. Cardiol Rev 2006;14(4):164-169 (Pubitemid 44350506)
90. Friedman RA, Leon AC. Expanding the Black Box - Depression, Antidepressants, and the Risk of Suicide. N Engl J Med 2007;356(23):2343-2346
91. Furukawa TA, Guyatt GH, Griffith LE. Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses. International Journal of Epidemiology 2002;31:72-76
92. Furukawa T A, McGuire H, Barbui C. Meta-analysis of effects and side effects of low dosage tricyclic antidepressants in depression: systematic review. BMJ 2002;325:991-995 (Pubitemid 35305144)
93. Furukawa TA, Cipriani A, Barbui C, Brambilla P, Watanabe N. Imputing response rates from means and standard deviations in metaanalysis.. International Clinical Psychopharmacology 2005;20:49-52. (Pubitemid 40105550)
94. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(1):7-10. (Pubitemid 41797469)
95. Geddes JR, Freemantle N, Mason J, Eccles MP, Boynton J. Selective serotonin reuptake inhibitors (SSRIs) for depression. Cochrane Database of Systematic Reviews 2000, Issue 2. [DOI: 10.1002/14651858.CD001851.pub2]
96. Geddes J, Butler R, Hatcher S, Cipriani A, Price J, Carney S, et al.Depressive disorders. Clinical Evidence 2004;12:1391-1436
97. Glassman AH, O'Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT Jr, Krishnan KR, van Zyl LT, Swenson JR, Finkel MS, Landau C, Shapiro PA, Pepine CJ, Mardekian J, Harrison WM, Barton D, Mclvor M, Sertraline Antidepressant Heart Attack Randomized Trial (SADHEART) Group. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002;288(6):701-709
98. Goldman LS, Nielsen NH, Champion HC. Awareness, diagnosis and treatment of depression. Journal of General Internal Medicine 1999;14(9):569-589
99. Guy W, Bonato RR. Manual for the ECDEU Assessment Battery.2. Chevy Chase, MD: National Institute of Mental Health, 1970.
100. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 1960;23:56-62.
101. Heym J, Koe BK. Pharmacology of sertraline: a review. Journal of Clinical Psychiatry 1988;49 Suppl 8:40-45
102. Higgins JP, Thompson SG, Deeks JJ, Altman DG.Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-560
103. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. Available from www.cochrane-handbook.org. The Cochrane Collaboration, 2008.
104. Imperadore G, Cipriani A, Signoretti A, Furukawa TA, Watanabe N, Churchill R, McGuire HF and Barbui C for the Meta-Analysis of New Generation Antidepressants (MANGA) Study Group. Citalopram versus other anti-depressive agents for depression. Cochrane Database of Systematic Reviews 2007, Issue 2.
105. Khan A, Khan SR, Walens G, Kolts R, Giller EL. Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports. Neuropsychopharmacology 2003;28:552-557
106. Koe BK, Weissman A, Welch WM, Browne RG. Sertraline, 1S,4S-N-methyl-4-(3, 4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthylamine, a new uptake inhibitor with selectivity for serotonin. Journal of Pharmacology and Experimental Therapeutics 1983;226(3):686-700.
107. Kupfer DJ, Frank E. Placebo in clinical trials for depression: complexity and necessity. JAMA 2002;287:1853-1854 (Pubitemid 34303631)
108. Lawrenson RA, Tyrer F, Newson RB. The treatment of depression in UK general practice: selective serotonin reuptake inhibitors and tricyclic antidepressants compared. Journal of Affective Disorders 2000;59:149-157 (Pubitemid 30317431)
109. Lespérance F, Frasure-Smith N, Koszycki D, et al.CREATE Investigators. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA 2007;297:367-379 (Pubitemid 46155798)
110. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003;326(7400):1167-1170 (Pubitemid 36649048)
111. Linde K, Berner MM, Kriston L. St John's wort for major depression. Cochrane Database of Systematic Reviews 2008, Issue 4.[Art. No.: CD000448. DOI: 10.1002/14651858.CD000448.pub3]
112. Lu M, Ades T. Assessing evidence consistency in mixed treatment comparisons. Journal of The American Statistical Association 2006;101:447-459
113. Luborsky L. Clinician's judgments of mental health. Archives of General Psychiatry 1962;7:407-417
114. Lumley S. Network meta-analysis for indirect treatment comparisons. Statistics in Medicine 2002;21:2313-2324
115. MacQueen G, Born L, Steiner M. The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders. CNS Drug Review 2001;7(1):1-24. (Pubitemid 32280681)
116. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 1979;134:382-389 (Pubitemid 9136500)
117. Montgomery JH, Byerly M, Carmody T, Li B, Miller DR, Varghese F, et al.An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia.. Controlled Clinical Trials 2004;25(6):598-612. (Pubitemid 39592864)
118. Nakagawa A, Watanabe N, Omori IM, Cipriani A, Barbui C, McGuire H, Churchill R and Furukawa TA for the MANGA study group. Milnacipran versus other anti-depressive agents for depression. Cochrane Database of Systematic Reviews 2007, Issue 2.
119. National Institute for Clinical Excellence. Depression: management of depression in primary and secondary care. Clinical Guideline 23, www.nice.org.uk/pdf/CG023quickrefguide.pdf (accessed 19th May 2005). London: National Institute for Clinical Excellence, 2004.
120. Nose M, Cipriani A, Furukawa TA, Omori IM, Churchill R, McGuire HF and Barbui C for the Meta-Analysis of New Generation Antidepressants (MANGA) Study Group. Duloxetine versus other anti-depressive agents for depression. Cochrane Database of Systematic Reviews 2007, Issue 2.
121. O'Connor CM, Glassman AH, Harrison DJ. Pharmacoeconomic analyses of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. J Clin Psychiatry 2005;66(3):346-52..
122. Omori I, Watanabe N, Nakagawa A, Cipriani A, Barbui C, McGuire H, Churchill R, Furukawa TA, Meta-Analysis of New Generation Antidepressants (MANGA) Study Group. Fluvoxamine versus other anti-depressive agents for depression. (Protocol). Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD006114]
123. Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses.. Annals of Internal Medicine 1992;116(1):78-84.
124. Parker G, Anderson IM, Haddad P. Clinical trials of antidepressant medications are producing meaningless results. Br J Psychiatry 2003;183:102-104 (Pubitemid 36963134)
125. Perlis RH, Perlis CS, Wu Y, Hwang C, Joseph M, Nierenberg AA. Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry.. American Journal of Psychiatry 2005;162(10):1957-1960 (Pubitemid 41428627)
126. Procyshyn RM, Chau A, Fortin P, Jenkins W. Prevalence and outcomes of pharmaceutical industry-sponsored clinical trials involving clozapine, risperidone, or olanzapine.. Canadian Journal of Psychiatry - Revue Canadienne De Psychiatrie 2004;49(9):601-606 (Pubitemid 39388352)
127. Quitkin FM, Harrison W, Stewart JW, McGrath PJ, Tricamo E, Ocepek-Welikson K, et al.Response to phenelzine and imipramine in placebo nonresponders with atypical depression. A new application of the crossover design. Archives of General Psychiatry 1991;48(4):319-323
128. Salanti G, Higgins JP, Ades A, Ioannidis JP. Evaluation of networks of randomized trials. Stat Methods Med Res 2008;17:279-301.
129. Smith D, Dempster C, Glanville J, Freemantle N, Anderson I. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: ameta-analysis. British Journal of Psychiatry 2002;180:396-404. (Pubitemid 34499333)
130. Thase ME. Relapse and recurrence in unipolar major depression: short-term and long-term approaches. J Clin Psychiatry 1990;51(Suppl):51-57. (Pubitemid 20212865)
131. Ware JE, Snow KK, Kosinski M, & Gandek B. SF-36 Health Survey Manual and Interpretation Guide. Boston, MA: New England Medical Centre, 1993.
132. Watanabe N, Omori I, Nakagawa A, Cipriani A, Barbui C, McGuire H, Churchill R, Furukawa TA, Meta-Analysis of New Generation Antidepressants (MANGA) Study Group. Mirtazapine versus other anti-depressive agents for depression (Protocol). Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD006528]
133. World Health Organization. The Ninth Revision of the International Classification of Diseases and Related Health Problems (ICD-9). Geneva: World Health Organization, 1978.
134. World Health Organization. The Tenth Revision of the International Classification of Diseases and Related Health Problems (ICD-10). Geneva: World Health Organization, 1982.
135. World Health Organisation. World Health Report 2001: Mental Health: New Understanding, New Hope. Geneva: World Health Organisation, 2001.
136. WHOQOL Group. The World Health Organization quality of life assessment (WHOQOL): Development and general psychometric properties. Social Science and Medicine 1998;46(12):1569-1665
137. Williams JW, Mulrow CD, Chiquette E. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary: clinical guidelines, Part 2. Annals of Internal Medicine 2000;132:743-756 (Pubitemid 30244176)
138. Wing J. Measuring mental health outcomes: a perspective from the Royal College of Psychiatrists. Outcomes into Clinical Practice. London: . London: BMJ Publishing, 1994, 1994.
139. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data.. Lancet 2004;363:1341-1345 (Pubitemid 38529872)
140. Zwarenstein M, Oxman A, Pragmatic Trials in Health Care Systems (PRACTIHC). Why are so few randomized trials useful, and what can we do about it?. J Clin Epidemiol 2006;59(11):1125-1126